Latent-Y: A Lab-Validated Autonomous Agent for De Novo Drug Design

Latent-Y represents a significant shift from 'AI models for biology' to 'AI agents for biology.' While many projects provide individual models (like ESM or AlphaFold), Latent-Y orchestrates these tools into a cohesive workflow that includes non-structural tasks like literature review and epitope identification. The defensibility score of 7 is driven by the 'lab-validated' nature of the project; in drug discovery, code is cheap but experimental validation is expensive and creates a significant moat. The quantitative signal (20 forks against 0 stars in just 9 days) is highly unusual and suggests immediate pick-up by the research community or professional labs before general 'star' momentum builds. The primary threat comes from frontier labs like Google DeepMind (Isomorphic Labs), who could integrate similar agentic workflows into their existing protein-folding platforms. However, the domain-specific nuance required for 'lab-ready' antibody selection provides a buffer. The displacement horizon is set to 1-2 years as the 'AI Scientist' paradigm becomes more competitive.